Keros Therapeutics, Inc. $KROS Shares Sold by Alkeon Capital Management LLC

Key Points

• Alkeon Capital Management LLC has reduced its holdings in Keros Therapeutics by 22.8%, owning 850,511 shares after selling 250,489 shares in the first quarter.
• Meanwhile, Vanguard Group Inc. and Federated Hermes Inc. significantly increased their stakes in Keros Therapeutics, with Vanguard boosting its holdings by 31.1% and Federated increasing by 882.3% during the same period.
• Keros Therapeutics recently reported an earnings per share (EPS) of ($0.76), surpassing the consensus estimate of ($1.14) by $0.38, despite revenue being significantly below expectations.

Alkeon Capital Management LLC lessened its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 22.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 850,511 shares of the company's stock after selling 250,489 shares during the quarter. Alkeon Capital Management LLC owned about 2.09% of Keros Therapeutics worth $8,667,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Two Sigma Investments LP boosted its stake in shares of Keros Therapeutics by 226.1% during the fourth quarter. Two Sigma Investments LP now owns 33,664 shares of the company's stock valued at $533,000 after acquiring an additional 23,342 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Keros Therapeutics during the fourth quarter worth $730,000. Jump Financial LLC purchased a new stake in shares of Keros Therapeutics in the first quarter valued at $1,058,000. Tejara Capital Ltd purchased a new stake in shares of Keros Therapeutics in the first quarter valued at $410,000. Finally, TFG Asset Management GP Ltd acquired a new position in Keros Therapeutics in the fourth quarter valued at $1,630,000. Hedge funds and other institutional investors own 71.56% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the company. Bank of America cut Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. Wedbush restated a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. HC Wainwright cut their price target on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Scotiabank decreased their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday, May 12th. Seven analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.00.

Keros Therapeutics Price Performance

NASDAQ KROS traded up $0.04 during trading hours on Friday, hitting $15.59. The company had a trading volume of 537,578 shares, compared to its average volume of 472,423. The firm's 50 day moving average is $14.39 and its 200 day moving average is $13.33. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The company has a market capitalization of $633.19 million, a price-to-earnings ratio of 50.29, a P/E/G ratio of 2.01 and a beta of 1.06.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $3.83 million. During the same quarter in the previous year, the firm posted ($1.25) earnings per share. The firm's quarterly revenue was up 49002.7% on a year-over-year basis. On average, equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.